High Mobility Group Box 1: a potential therapeutic target for systemic lupus erythematosus.
High Mobility Group Box 1 (HMGB1) is a nuclear protein participating in chromatin architecture and transcriptional regulation. Recently, there is increasing evidence that HMGB1 contributes to the pathogenesis of chronic inflammatory and autoimmune diseases due to its pro-inflammatory and immunostimulatory properties. Elevated expression of HMGB1 was found in the sera of patients and mice with systemic lupus erythematosus (SLE). In addition, it has been shown that HMGB1 may act as a proinflammatory mediator in antibody-induced kidney damage in SLE. All theses findings suggest that HMGB1 have important biological effects in autoimmunity that might be a promising therapeutic target for SLE. In this review, we will briefly discuss the biological features of HMGB1 and summarize recent advances on the role of HMGB1 in the pathogenesis and treatment of SLE.
Pan
Hai-Feng
HF
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Anhui, People's Republic of China. panhaifeng1982@gmail.com
Wu
Guo-Cui
GC
Li
Wei-Ping
WP
Li
Xiang-Pei
XP
Ye
Dong-Qing
DQ
D000818:Animals; D015551:Autoimmunity / Q000235:genetics*; D004247:DNA / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000235:genetics*; D024243:HMGB1 Protein / Q000097:blood* / Q000235:genetics; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D051379:Mice
D024243:HMGB1 Protein; D004247:DNA